Sugi Predict

Sugi Predict / Compounds / SCHEMBL1480754

SCHEMBL1480754

SCHEMBL1480754

Clc1ccc(-c2c[nH]c(C=Cc3ccc(-c4ccc(Oc5ccccc5)cc4)cc3)n2)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 2/20 0.40
▸ BCL2L1 Q07817 1/20 0.40
▸ BACE1 P56817 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ DHODH Q02127 1/20 0.38
▸ CXCR2 P25025 1/20 0.38
▸ PTGES O14684 1/20 0.38
▸ TUBB4A P04350 2/20 0.36
▸ TUBB P07437 2/20 0.36
▸ TUBA3C P0DPH7 2/20 0.36
▸ TUBA1B P68363 2/20 0.36
▸ TUBA4A P68366 2/20 0.36
▸ TUBB4B P68371 2/20 0.36
▸ TUBB3 Q13509 2/20 0.36
▸ TUBB2A Q13885 2/20 0.36
▸ TUBB8 Q3ZCM7 2/20 0.36
▸ TUBA3E Q6PEY2 2/20 0.36
▸ TUBA1A Q71U36 2/20 0.36
▸ TUBA1C Q9BQE3 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480751 1.00 MCL1 (0.40) MCL1BCL2L1BACE1KDM4EMAPT
SCHEMBL1480764 0.91 PTGES (0.44) BACE1KDM4EMAPTPTGESTUBB4A
SCHEMBL1480766 0.91 PTGES (0.44) BACE1KDM4EMAPTPTGESTUBB4A
SCHEMBL1480851 0.87 BACE1 (0.51) MCL1BCL2L1BACE1CNR1ALOX5
SCHEMBL1480854 0.87 BACE1 (0.51) MCL1BCL2L1BACE1CNR1ALOX5
SCHEMBL1481070 0.87 MAPT (0.44) KDM4EMAPTCXCR2CNR1CNR2
SCHEMBL1481066 0.87 MAPT (0.44) KDM4EMAPTCXCR2CNR1CNR2
SCHEMBL1481354 0.86 TUBB4A (0.46) KDM4EMAPTCXCR2TUBB4ATUBB
SCHEMBL1481357 0.86 TUBB4A (0.46) KDM4EMAPTCXCR2TUBB4ATUBB
SCHEMBL1481332 0.85 ALDH1A3 (0.43) BACE1KDM4EMAPTCXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 — — US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 — — EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 — — WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 — — US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MCL1 3569/4885BCL2L1 1467/4885BACE1 4200/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MCL1 3569/4885BCL2L1 1467/4885BACE1 4200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.